Business Standard

Monday, December 23, 2024 | 08:52 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Gilead's experimental Covid-19 drug remdesivir fails first trial: Reports

Researchers studied 237 patients, giving the drug to 158 and comparing their progress with the remaining 79

A medic collects a swab sample of a man from a new swab testing cabin at Podar hospital in Worli during a nationwide lockdown in the wake of coronavirus pandemic, in Mumbai. Photo: PTI
Premium

A medic collects a swab sample of a man from a new swab testing cabin at Podar hospital in Worli during a nationwide lockdown in the wake of coronavirus pandemic, in Mumbai. Photo: PTI

Reuters
Gilead Sciences Inc’s experimental coronavirus drug failed its first randomised clinical trial, the Financial Times reported on Thursday, citing draft documents published accidentally by the World Health Organization.

Trading in the shares of the company was halted after they fell 6%.

The Chinese trial showed the antiviral remdesivir did not improve patients' condition or reduce the pathogen's presence in the bloodstream, the report on.ft.com/2VumJIA said.
Researchers studied 237 patients, giving the drug to 158 and comparing their progress with the remaining 79. The drug also showed

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in